J&J eyes rare disease expansion for blockbuster-to-be Imaavy with trial win

Just 16 months after Johnson & Johnson scored its initial FDA app | Sixteen months after Johnson & Johnson scored its initial FDA…

fiercepharma.com17 g fa

New data suggest Imaavy could be an effective treatment for autoimmune anemia. Elsewhere, Enliven detailed data for a Merck…

biopharmadive.com3 mesi fa

In a plenary session at the 2026 European Hematology Association (EHA) annual meeting in Stockholm, Johnson & Johnson brought to…

fiercepharma.com3 mesi fa

Johnson & Johnson has unveiled massive phase 3 survival data for its dual bispecific combination in earlier-line multiple…

fiercepharma.com1 mese fa

J&J's Imaavy approved for warm autoimmune hemolytic anemia; Takeda's Orzeyful & Rhythm's Imcivree approved in Japan; Basking's…

endpoints.news16 g fa

It’s been seven years since Pfizer scored an expansion for its breast cancer blockbuster Ibrance, and during that time, the drug…

fiercepharma.com2 mesi fa

Other newsrooms on this story